The 7th ISCC
December 2-3, 2002
Keidanren Hall
December 2, 2002 (Mon)
13:00 - 13:10
Haruo Sugano (Cancer Chemotherapy Center, Tokyo)
Welcome and Introduction
I Drug Development based on Genome Science
Chairpersons: Robert H. Shoemaker (NCI-Frederick, Frederick)
Nagahiro
Saijo (National Cancer Center Hosp., Tokyo)
13:10–13:50
David G. Covell (NCI-Frederick, Frederick)
Relating anticancer drug screening data to structural features of chemical libraries
13:50–14:20
Yoichi Furukawa (Univ. Tokyo, Tokyo)
Identification and characterization of novel molecular targets for cancer
chemotherapy using genome-wide cDNA microarray
14:20–14:50
Hiroyuki Aburatani (Univ. Tokyo, Tokyo)
Transcriptome analysis for cancer therapeutics
14:50–15:00
Discussion
15:00–15:20
Coffee Break
15:20–16:00
Ron van Schaik (Erasmus Medical Center, Rotterdam)
Pharmacogenetics
16:00–16:30
Yoshio Miki (Japanese Foundation for Cancer Research and Tokyo Medical Dental Univ., Tokyo)
Large-scale genomic studies in cancer patients for personalized chemotherapy
16:30–16:40
Discussion
II New Mechanism of Drug Resistance
Chairpersons: David G. Covell (NCI-Frederick, Frederick)
Ryuzo
Ueda (Nagoya City Univ., Nagoya)
16:40–17:10
Yoshikazu Sugimoto (Cancer Chemotherapy Center, Tokyo)
Breast cancer resistance protein (BCRP): physiological substrates, reversing
agents and SNPs
17:10 - 17:40
Kazuto Nishio (National Cancer Center Research Institute, Tokyo)
Resistance mechanism of ZD1839
17:40–18:00
Discussion
18:00–19:00
Mixer
December 3, 2002 (Tue)
III New Anticancer Agents under Clinical Considerations
Chairpersons: Edward A. Sausville (NCI, Bethesda)
Masahiro
Fukuoka (Kinki Univ, Osaka)
09:30–09:55
Saburo Sone (Tokushima Univ., Tokushima)
ZD6126 (tublin binding inhibitor, vascular targeting agent)
09:55–10:20
Nobuyuki Yamamoto (Shizuoka Cancer Center Hospital, Shizuoka)
TZT-1027
10:20–10:40
Coffee Break
10:40–11:05
Masanori Suzuki (Daiichi Pharmaceutical Co., Ltd., Tokyo)
Preliminary results of DE-310 (macromolecular carrier conjugated DX-8951) phase I studies
11:05–11:30
Jun Ohtsu (National Cancer Center Hospital, Tokyo)
Oxaliplatin
11:30–12:10
Manuel Hidalgo (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore)
mTOR inhibitor
12:10–12:20
Discussion
12:20–13:30
Lunch Break
IV Kinases as Targets
Chairpersons: Manuel Hidalgo (The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins, Baltimore)
Yutaka Ariyoshi (Aichi Hosp., Nagoya)
13:30–13:55
Masakazu Toi (Tokyo Metropolitan Komagome Hospital, Tokyo)
Herceptin: Its current topics and future perspectives
13:55–14:20
Kiyoshi Yokokawa (Takeda Chemical Industries, Ltd., Tokyo)
TAK165
14:20–14:45
Kazuhiko Nakagawa (Kinki Univ., Osaka)
EGFR tyrosine kinase inhibitors: ZD1839 and ZD6474
14:45–15:25
Jaap Verweij (Rotterdam Cancer Institute, Rotterdam)
Glivec for GIST, a new paradigm for the treatment of solid tumors
15:25–15:35
Discussion
15:35–15:55
Coffee Break
V Target-based Drug Development
Chairpersons: Jaap Verweij (Rotterdam Cancer Institute,
Rotterdam)
Takashi Tsuruo (Univ. Tokyo, Tokyo)
15:55–16:20
Naoya Fujita (Univ. Tokyo, Tokyo)
Akt/PKB pathway as a promising target for cancer chemotherapy
16:20–17:00
Robert H. Shoemaker (NCI-Frederick, Frederick)
Targeting the HIF-1 alpha signaling pathway for cancer therapy
17:00–17:40
Edward A. Sausville (NCI, Bethesda)
Novel DNA-damaging strategies
17:40–17:50
Discussion
17:50 - 18:00
Takashi Tsuruo (Univ. Tokyo, Tokyo)
Closing Remark
